Reprogramming metastatic tumour cells with embryonic microenvironments

Nature Reviews Cancer

Volumn 7, Issue 4, 2007, Pages 246-255

  Hendrix, Mary J C ^a   Seftor, Elisabeth A ^a   Seftor, Richard E B ^a   Kasemeier Kulesa, Jennifer ^b   Kulesa, Paul M ^b   Postovit, Lynne Marie ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; PROTEIN NODAL;

CANCER STEM CELL; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL TYPE; DNA MODIFICATION; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; MELANOMA; METASTASIS; MICROENVIRONMENT; MULTIPOTENT STEM CELL; NEURAL CREST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; EMBRYO; EMBRYONIC STEM CELLS; HUMANS; MELANOMA; MODELS, ANIMAL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEURAL CREST; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; ZEBRAFISH;

EID: 33947583623     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc2108     Document Type: Review

References (103)

1. Topczewska, J. M. et al. Embryonic and tumorigenic pathways converge via Nodal signalling: role in melanoma aggressiveness. Nature Med. 12, 925-932 (2006). This is the first paper to report the discovery of Nodal expression in melanoma and demonstrate its association with tumour cell plasticity and progression.
2. Sell, S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51, 1-28 (2004).
3. Clarke, M. F. et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66, 9339-9344 (2006).
4. Li, L. & Neaves, W. B. Normal stem cells and cancer stem cells: The niche matters. Cancer Res. 66, 4553-4557 (2006).
5. Tan, B. T., Park, C. Y., Ailles, L. E. & Weissman, I. L. The cancer stem cell hypothesis: a work in progress. Lab. Investig. 86, 1203-1207 (2006).
6. Monk, M. & Holding, C. Human embryonic genes re-expressed in cancer cells. Oncogene 20, 8085-8089 (2001).
7. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
8. Fang, D. et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328-9337 (2005).
9. Houghton, J. et al. Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571 (2004).
10. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
11. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001). This paper provides a comprehensive review of stem cells, both normal and cancer.
12. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
13. Grichnik, J. M. et al. Melanoma, a tumour based on a mutant stem cell? J. Investig. Dermatol. 126, 142-153 (2006).
14. Virchow, R. L. K. in Cellular Pathology (ed. Hirschwald, A.) (Berlin, 1858).
15. Garraway, L. A. & Sellers, W. R. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Rev. Cancer 6, 593-602 (2006).
16. Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA. 72, 3585-3589 (1975). This seminal study was one of the first to illuminate the ability of embryonic microenvironments to reprogramme tumour cells. Specifically, the embryonic blastocyst microenvironment of the mouse was shown to suppress the tumourigenic phenotype of teratocarcinoma cells.
17. Pierce, G. B., Pantazis, C. G., Caldwell, J. E. & Wells, R. S. Specificity of the control of tumour formation by the blastocyst. Cancer Res. 42, 1082-1087 (1982).
18. Gerschenson, M., Graves, K., Carson, S. D., Wells, R. S. & Pierce, G. B. Regulation of melanoma by the embryonic skin. Proc. Natl Acad. Sci. USA 83, 7307-7310 (1986).
19. Podesta, A. H., Mullins, J., Pierce, G. B. & Wells, R. S. The neurula stage mouse embryo in control of neuroblastoma. Proc. Natl Acad. Sci. USA 81, 7608-7611 (1984).
20. Dolberg, D. S. & Bissell, M. J. Inability of Rous sarcoma virus to cause sarcomas in the avian embryo. Nature 309, 552-556 (1984).
21. Bittner, M. et al. Molecular classifcaiton of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000). This was the first report to provide a molecular signature of cutaneous melanoma demonstrating multiple subclasses of the disease.
22. Carr, K. M., Bittner, M. & Trent, J. M. Gene-expression profiling in human cutaneous melanoma. Oncogene 22, 3076-3080 (2002).
23. Hoek, K. et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanoma. Cancer Res. 64, 570-582 (2004).
24. Gao, C.-F. et al. Proliferation and invasion: plasticity in tumour cells. Proc. Natl Acad. Sci. USA 102, 10528-10533 (2005).
25. Luo, J. et al. Human prostatic cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res. 61, 4683-4688 (2001).
26. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
27. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathologies. Cancer Cell 10, 529-541 (2006).
28. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genomewide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
29. Lamb, J. et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1936 (2006).
30. Lotem, J. & Sachs, L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 25, 7663-7672 (2006).
31. Ivanova, N. B. et al. A stem cell molecular signature. Science 298, 601-604 (2002). This paper used global gene analyses to illuminate the molecular signature of stem cells.
32. Boyer, L. A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947-956 (2005).
33. Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am. J. Pathol. 155, 739-752 (1999).
34. Maniotis, A. J. et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab. Invest. 82, 1031-1034 (2002).
35. Ruf, W. et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 63, 5381-5389 (2003).
36. Dome, B., Hendrix, M. J. C., Pahu, S., Tovari, J. & Timar, J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am. J Pathol. 170, 1-15 (2007).
37. Hendrix, M. J. C. et al. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res. 62, 665-668 (2002).
38. Sun, B., Zhang, S., Zhao, X., Zhang, W. & Hao, X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int. J. Oncol. 25, 1609-1614 (2004).
39. Sun, B. et al. Vasculogenic mimicry is associated with high tumour grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol. Rep. 16, 693-698 (2006).
40. Basu, G. D. et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res. 8, R69 (2006).
41. Chung, L. W. et al. Stromal-epithelial interaction in prostate cancer progression. Clin. Genitourin Cancer 5, 162-170 (2006).
42. van der Schaft, D. W. et al. Tumour cell plasticity in Ewing sarcoma, and alternative circulatory system by hypoxia. Cancer Res. 65, 11520-11528 (2005).
43. Hendrix, M. J. C, Seftor, E. A., Hess, A. R. & Seftor, R. E. B. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev. Cancer 3, 411-421 (2003). This review highlights the molecular underpinnings of melanoma tumour cell plasticity, including vasculogenic mimicry.
44. Du, J. et al. MELANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am. J. Pathol. 163, 333-343 (2003).
45. Hendrix, M. J. C., Seftor, E. A., Hess, A. R. & Seftor, R. E. B. in From melanocytes to malignant melnoma. (eds Hearing V. J., Leong, S. P. L.) 533-550 (Humana Press, Totowa, 2005).
46. Takeuchi, H., Kuo, C., Morton, D. L., Wang, H. J. & Hoon, D. S. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 63, 441-448 (2003).
47. Postovit, L. M., Seftor, E. A., Seftor, R. E. B. & Hendrix, M. J. C. A 3-D model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 24, 501-505 (2006). This paper describes a new model designed to examine the effects of the microenvironment on cell behaviour. Using this model, the microenvironment of hESCs was shown to reprogramme aggressive melanoma cells towards a less aggressive melanocytic-like phenotype.
48. Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
49. Schatten, G. et al. Culture of human embryonic stem cells. Nature Methods 2, 455-463 (2005).
50. Levenberg, S. et al. Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc. Natl Acad. Sci. USA 100, 12741-12746 (2003).
51. Ezashi, T., Das, P. & Roberts, R. M. Low O2 tensions and the prevention of differentiation of hES cells. Proc. Natl Acad. Sci. USA 102, 4783-4788 (2005).
52. Ramalho-Santos, M., et al. 'Stemness': transcriptional profiling of embryonic and adult stem cells. Science 298, 597-600 (2002).
53. Weissman, I. L. Stem cells: units of development, units of regeneration, and units in evolution. Cell 100, 157-168 (2000).
54. Silva, G. A. et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303, 1352-1355 (2004).
55. Xu, R. H. et al. Basic FGF and suppression of BMP signalling sustain undifferentiated proliferation of human ES cells. Nature Methods 2, 185-190 (2005).
56. Postovit, L.-M. et al. The convergence of embryonic and tumorigenic signalling pathways contribute to tumour cell plasticity. Proceedings ASCB 43, B692 (2006).
57. Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Molecular plasticity of human melanoma cells. Oncogene 19, 3070-3075 (2003).
58. Balint, K. et al. Activation of Notch1 signalling is required for beta-catenin-mediated human primary melanoma progression. J. Clin. Invest. 115, 3166-3176 (2005).
59. Weeraratna, A. T. et al. Wnt5a signalling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288 (2002).
60. De Robertis, E. M., Larrain, J., Oelgeschlager, M. & Wessely, O. The establishment of Spemann's organizer and patterning of the vertebrate embryo. Nature Rev. Genet. 1, 171-181 (2000).
61. Schier, A. F. Nodal signalling in vertebrate development. Annu. Rev. Cell Dev. Biol. 19, 589-621 (2003). This paper provides an in-depth overview of the Nodal signalling pathway, as well as its function as an embryonic morphogen.
62. Toyama, R., O'Connell, M. L., Wright, C. V., Kuehn, M. R. & Dawid, I. B. Nodal induces ectopic goosecoid and lim1 expression and axis duplication in zebrafish. Development 121, 383-391 (1995).
63. Thisse, B., Wright, C. V. E. & Thisse, C. Activin- and Nodal-related factors control antero-posterior patterning of the zebrafish embryo. Nature 403, 425-428 (2000).
64. Cucina, A. et al. Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). Apoptosis 11, 1617-1628 (2006).
65. Lee, L. M., Seftor, E. A., Bonde, G., Cornell, R. A. & Hendrix, M. J. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumour formation. Dev. Dyn. 233, 1560-1570 (2005).
66. Haldi, M., Ton, C., Seng, W. L. & McGrath, P. Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9, 139-151 (2006).
67. LeDouarin, N. & Kalcheim, C. The Neural Crest. Cambridge Univ. Press, Cambridge, UK (1999).
68. Trainor, P. & Krumlauf, R. Patterning the cranial neural crest: hindbrain segmentation and Hox gene plasticity. Nature Rev. Neuro. 1, 116-124 (2000).
69. Kontges, G. & Lumsden, A. Rhombencephalic neural crest segmentation is preserved throughout craniofacial ontogeny. Development 122, 3229-3242 (1996).
70. Dupin, E. & LeDouarin, N. Development of melanocyte precursors from the vertebrate neural crest. Oncogene 22, 3016-3023 (2003)
71. Harris, M. & Erickson, C. Lineage specification in neural crest cell pathfinding. Dev. Dyn. 236, 1-19 (2007).
72. Noden, D. The role of the neural crest in patterning of avian cranial skeletal, connective, and muscle tissues. Dev. Biol. 96, 144-165 (1983).
73. Lumsden, A., Sprawson, N. & Graham, A. Segmental origin and migration of neural crest cells in the hindbrain region of the chick embryo. Development 113, 1281-1291 (1991).
74. Trainor, P. & Krumlauf, R. Plasticity in mouse neural crest cells reveals a new patterning role for cranial mesoderm. Nature Cell Biol. 2, 96-102 (2000).
75. Graham, A., Heyman, I. & Lumsden, A. Even-numbered rhombomeres control the apoptotic elimination of neural crest cells from odd-numbered rhombomeres in the chick hindbrain. Development 119, 233-245 (1993).
76. Grapin-Botton, A. et al. Plasticity of transposed rhombomeres: Hox gene induction is correlated with phenotypic modifications. Development 121, 2707-2721 (1995).
77. Schilling, T., Prince, V. & Ingham, P. Plasticity in zebrafish Hox expression in the hindbrain and cranial neural crest. Dev. Biol. 231, 201-216 (2001).
78. Kulesa, P. & Fraser, S. Neural crest cell dynamics revealed by time-lapse video microscopy of whole chick explant cultures. Dev. Biol. 204, 327-344 (1998).
79. Schilling, T. & Kimmel, C. Segment and cell type lineage restrictions during pharyngeal arch development in the zebrafish embryo. Development 120, 483-494 (1994).
80. Smith, A. et al. The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand regulate targeted migration of branchial neural crest cells. Curr. Biol. 7, 561-570 (1997).
81. Farlie, P. et al. A paraxial exclusion zone creates patterned cranial neural crest cell outgrowth adjacent to rhombomeres 3 and 5. Dev. Biol. 213, 70-84 (1999).
82. Kulesa, P. et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc. Natl Acad. Sci. USA 103, 3752-3757 (2006). This paper illustrates the ability of the chick embryonic neural crest to reprogramme metastatic melanoma cells towards neural-crest associated phenotypes.
83. Real, C. et al. Clonally cultured differentiated pigment cells can dedifferentiate and generate multipotent progenitors with self-renewal potential. Dev. Biol. 300, 656-669 (2006).
84. Erickson, C., Tosney, K. & Weston, J. Analysis of migratory behavior of neural crest and fibroblastic cells in embryonic tissues. Dev. Biol. 77, 142-156 (1980).
85. Oppitz, M. et al. Non-malignant migration of B16 mouse melanoma cells in the neural crest and invasive growth in the eye cup of the chick embryo. Melanoma Res. 1, 17-30 (2007).
86. Teddy, J. & Kulesa, P. In vivo evidence for short- and long-range cell communication in cranial neural crest cells. Development 131, 6141-6151 (2004).
87. Young, H. et al. Dynamics of neural crest-derived cell migration in the embryonic mouse gut. Dev. Biol. 270, 455-473 (2004).
88. Drukenbrod, N. & Epstein, M. Behavior of enteric neural crest-derived cells varies with respect to the migratory wavefront. Dev. Dyn. 236, 84-92 (2007).
89. Chen, C. & Shen, M. M. Two modes by which Lefty proteins inhibit Nodal signalling. Curr. Biol. 14, 618-624.
90. Postovit, L. M. et al. The commonality of plasticity underlying multipotent tumour cells and embryonic stem cells. J. Cell Biochem. 19 December 2006 [Epub ahead of print].
91. The Cancer Genome Anatomy Project. SAGE Anatomic Viewer. CGAP [online], http://cgap.nci.nih.gov/SAGE/AnatomicViewer (2007).
92. Mesnard, D., Guzman-Ayala, M. & Constam, D. B. Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. Development 133, 2497-2505 (2006).
93. Jager, D., Jager, E. & Knuth, A. Immune response to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54, 669-673 (2001).
94. Gibbs, W. W. Nanobodies. Sci. Am. 293, 78-83 (2005).
95. Strizzi, L., Bianco, C., Normanno, N. & Salomon, D. Cripto-1: A multifunciontal modulator during embryogenesis and angiogenesis. Oncogene 24, 5731-5741 (2005).
96. Minchiotti, G. Nodal-dependant Cripto signalling in ES cells: from stem cells to tumour biology. Oncogene 24, 5668-5675 (2005).
97. Bianco, C. et al. Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin. Cancer Res. 12, 5158-5164 (2006).
98. Strizzi, L. et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J. Cell Physiol. 201, 266-276 (2004).
99. Normanno, N. et al. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J. Cell Physiol. 198, 31-39 (2004).
100. Brandt, R. et al. Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. J. Biol. Chem. 269, 17320-17328 (1994).
101. Bianco, C. et al. A nodal- and ALK4-independent signalling pathway activated by Cripto-1 through glypican-1 and c-Src. Cancer Res. 63, 1192-1197 (2003).
102. Adkins, H. B. et al. Antibody blockade of the Cripto CFC domain suppresses tumour cell growth in vivo. J. Clin. Invest. 112, 575-587 (2003). This paper demonstrates the importance of targeting Cripto on cancer cells as a rational therapeutic strategy.
103. Xing, P. X., Hu, X. F., Pietersz, G. A., Hosick, H. L. & McKenzie, I. F. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res. 64, 4018-4023 (2004).